Skip to main content

Advertisement

Table 1 Doses used for drug administration a

From: The effect of osteopontin and osteopontin-derived peptides on preterm brain injury

  Intracerebroventricular administration Intranasal administration
rmOPN N134–153 C154–198 rmOPN T-OPN N134–153
Dose (μg/pup) 0.05 0.2 0.5 1.2 1.2 30
Concentration (μg/μl) 0.025 0.1 0.25 0.2 0.2 5
Volume (μl) 2 2 2 6 6 6
  1. aC154–198, Osteopontin C-terminal residues 154 to 198; N134–153, Osteopontin N-terminal residues 134 to 153; rmOPN, Recombinant mouse osteopontin; T-OPN, Thrombin-cleaved osteopontin.